These are trial averages under study conditions, not guaranteed outcomes
Most often, decreasing the dose or pausing therapy will improve minor-to-moderate gastrointestinal symptoms
At the same time, recent clinical studies have reported beneficial effects in conditions such as osteoarthritis and psoriatic arthritis, he said
Despite GIP-R agonism having been linked to enhanced glucagon levels [40], treatment with all doses tirzepatide have surprisingly been associated with significantly reduced levels of fasting glucagon more than placebo [76] and dulaglutide [74]
We start with the dominant symptom, monitor response, and add therapies in a staged fashion, always weighing metabolic and oncologic risks
New England Journal of Medicine , 384 (11), 9891002